Novo Nordisk Targets Japan Self-Pay Market as Only 14,000 Access Obesity Drugs [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
Novo Nordisk ( NYSE:NVO ) is testing a new route to unlock obesity drug demand in Japan, where strict reimbursement rules have slowed uptake despite rising global interest in GLP-1 therapies. The Danish drugmaker said it will work with physicians and patients to enable self-funded treatment pathways for drugs such as Wegovy, targeting those willing to pay out of pocket. Management indicated the move is aimed at reaching patients who are currently unable to access treatment under existing insurance constraints, which have created a bottleneck in a market with growing clinical need. Warning! GuruFocus has detected 2 Warning Sign with NVO. Is NVO fairly valued? Test your thesis with our free DCF calculator. The scale of that gap is notable. Wegovy has been available in Japan since February 2024, yet only about 14,000 people are currently receiving obesity drugs, compared with roughly 6 million who meet treatment criteria and a broader 26.6 million classified as obese. Access remai
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- The Daily Chase: Energy prices surge as strikes on gulf facilities escalate [BNN Bloomberg (Canada)]BNN Bloomberg
- 1 Reason I'm Never Selling Novo Nordisk Stock [Yahoo! Finance]Yahoo! Finance
- Lilly's next-gen obesity drug shows reduction in blood sugar levels in trial [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk patent expiry opens door to cheaper weight-loss drugs in India [Yahoo! Finance]Yahoo! Finance
- Ozempic Is About to Go Generic in India, China and Canada [The New York Times]The New York Times
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 3/17/26 - Form 6-K
- 3/9/26 - Form 6-K
- 3/2/26 - Form 6-K
- NVO's page on the SEC website